The report notes Alembic is expected to underperform peers with DF sales growth of 6.8% YoY owing to muted performance in acute and chronic segments, though it also expects 55% YoY US growth supported by Bosutinib exclusivity.
Read this note →Alembic Pharmaceuticals Limited
NSE APLLTD BSE 533573 INE901L01018
0 filings · 0 analysed
1,019.90
+0.15%
over today
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing.
What the desks said
Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief